Several legal developments related to pharmaceutical pricing in 2026 have had the industry scrambling to understand and calculate the impacts. From the implementation of a negotiated “maximum fair price” for selected top selling products to efforts toward “most favored nation” pricing for all to a push to direct-to-consumer offerings to varied state laws to the uncertainty of federal action related to the 340B program and regulating pharmacy benefit managers, industry stakeholders expected 2026 to be a tumultuous year. In this presentation, Aurora Kammerer and Beth Siemer will outline the legal underpinnings of these dynamics and check in on impacts and what to expect going forward.
Health Law Navigator – Pharmaceutical Pricing in 2026: Dramatic Changes or More of the Same?
March 11, 2026
12:00 p.m. - 1:00 p.m. CT